Determination of degradation products of squalamine lactate using LC/MS

Journal of Pharmaceutical and Biomedical Analysis

Volumn 32, Issue 1, 2003, Pages 85-96

  Li, Cong Jun ^a,b   Kari, U Prasad ^a   Noecker, Lincoln A ^a   Jones, Stephen R ^a   Sabo, Andrew M ^a   McCormick, Timothy J ^a   Johnston, Sean M ^a  

^a Genaera Corporation   (United States)

^b 206 Carnegie Center   (United States)

Author keywords

Degradation; LC MS; Squalamine

Indexed keywords

BUFFER; SQUALAMINE LACTATE; STEROID; SULFATE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DEGRADATION; DRUG DETERMINATION; DRUG STABILITY; DRUG STRUCTURE; HEAT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; PH; PRIORITY JOURNAL; TEMPERATURE;

EID: 0037464431     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(03)00047-5     Document Type: Article

References (8)

1. Moore K.S., Wehrli S., Roder H., Rogers M., Forest J.N. Jr., McCrimmon D., Zasloff M. Proc. Natl. Acad. Sci. USA. 90:1993;1354-1358.
2. Sills A.K. Jr., Williams J.I., Tyler B.M., Epstein D.S., Sipos E.P., Davis J.D., McLane M.P., Pitchford S., Cheshire K., Gannon F.H., Kinney W.A., Chao T.L., Donowitz M., Laterra J., Zasloff M., Brem H. Cancer Res. 58:1998;2784-2792.
3. Teicher B.A., Williams J.I., Takeuchi H., Ara G., Herbst R.S., Buxton D. Cancer Res. 58:1998;2567-2792.
4. Schiller J.A., Bittner G. Clin. Cancer Res. 5:1999;4287-4294.
5. Li D., Williams J.I., Pietras R.J. Oncogene. 21:2002;2805-2814.
6. 13C signals at δ 22.85, 26.23 and 174.46, respectively; Key COSY45 correlations: From signal at δ 7.75 to signal at δ 3.09; From signal at δ 3.94 to signal at δ 1.20.
7. C.-J. Li, et al., J. Pharm. Biomed. Anal., submitted for publication.
8. Wehrli S.L., Moore K.S., Roder H., Durell S., Zasloff M. Steroids. 58:1993;370-378.